A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

计划入组 64 人 · 首次发布于 2026 年 7 月 16 日

RESET System Pivotal Trial (Rev F)

计划入组 264 人 · 首次发布于 2019 年 9 月 24 日

Butterfly Sensor With Rev K Version

计划入组 9 人 · 首次发布于 2013 年 11 月 25 日

GH-56

REV-123

REV-0100

NEUROTAU, INC.

United States

MDI Therapeutics, Inc.

United States

慈利县和气气体厂

Revagenix Doses First Participant in Phase 1 Trial of Rev-56, a First-in-Class Inhaled Anti-Pseudomonal Therapy for Non-CF Bronchiectasis

Praxis Precision Medicines Reports 56% Seizure Reduction with Vormatrigine Despite Stock Decline

ImmunityBio Launches Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma